GSK sets out new transparency policy

12th October 2012

Britain’s biggest drug manufacturer GlaxoSmithKline has unveiled a new transparency policy under which data from clinical trials will be made more widely available.

The decision to share information from its studies comes three months after GSK was fined $3bn (£1.9bn) for fraud related to concealing safety issues. Chief executive Sir Andrew Witty explained the company will set up an independent panel of experts to review and approve requests from researchers to access the data in a move that is a "first" for a pharmaceutical company.